NCT04350606View on ClinicalTrials.gov

A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia

PHASE3CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 25, 2020

Primary Completion Date

January 22, 2021

Study Completion Date

April 19, 2021

Conditions
Aplastic Anemia
Interventions
BIOLOGICAL

PF-06462700

PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.

Trial Locations (3)

466-8560

Nagoya University Hospital, Nagoya

329 0498

Jichi Medical University Hospital, Shimotsuke

160-8582

Keio University Hospital, Shinjuku-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04350606 - A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia | Biotech Hunter | Biotech Hunter